CanSino Biologics Inc. announced that, the phase I trial for the absorbed diphtheria, tetanus and acellular pertussis combined vaccine (for people aged six years old and above) (the "Tdcp Adolescent and Adult") developed by the Company, was officially initiated recently and the first trial patient case has been formally enrolled. The Tdcp Adolescent and Adult is a booster vaccine for diphtheria, tetanus and acellular pertussis for adolescents and adults aged six years old and above. Major developed countries have incorporated the vaccine into their routine vaccination programs, but there isn't any approved booster vaccine for diphtheria, tetanus and acellular pertussis for adolescents and adults in China.

If successfully launched, the product will fill in the gap in the domestic market. The manufacturing process of the co-purified diphtheria, tetanus and acellular pertussis vaccine currently available in China uses a process of co-purification of pertussis antigens. As a diphtheria, tetanus and acellular pertussis (components) vaccine, each pertussis antigen of the Tdcp Adolescent and Adult can be purified separately and formulated in a defined ratio, thus ensuring batch-to-batch consistency of product quality and making the product more stable.